ClinicalTrials.gov
ClinicalTrials.gov Menu

Pseudohyponatremia of Multiple Myeloma is True Hyponatremia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01425606
Recruitment Status : Unknown
Verified August 2011 by Meir Medical Center.
Recruitment status was:  Not yet recruiting
First Posted : August 30, 2011
Last Update Posted : August 30, 2011
Sponsor:
Information provided by (Responsible Party):
Meir Medical Center

Brief Summary:
Hypothesis: the hyponatremia of multiple myeloma (m.m.)is true and not pseudohyponatremia by using the stewart approach to acid - base interpretation, would like to show that the positive charged m- proteins produced in m.m.result in true hyponatremia.

Condition or disease Intervention/treatment
Hyponatremia of Multiple Myeloma Other: blood test

Study Type : Observational
Estimated Enrollment : 50 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: a Study to Evaluate the Electrolyte Changes in Particular Sodium,in Multiple Myeloma and the Effect of the m- Proteins on the Strong Ion Difference
Study Start Date : September 2011
Estimated Primary Completion Date : June 2012
Estimated Study Completion Date : June 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Multiple Myeloma
U.S. FDA Resources

Group/Cohort Intervention/treatment
blood test
to measure levels of sodium, albumin and acid - base status in venous blood
Other: blood test
blood test to measure levels of: sodium, albumin and acid - base status in venous blood.



Primary Outcome Measures :
  1. hyponatremia present or not [ Time Frame: one year ]
  2. hyponatremia [ Time Frame: one year ]
    pseoudohyponatremia or not



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
patients with gammaglobulinemia and\or multiple myeloma.
Criteria

Inclusion Criteria:

  • patients with multiple myeloma

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01425606


Locations
Israel
Meir Hospital Not yet recruiting
Kfar Saba, Israel
Contact: jeffrey sachs, MBChB    97297471545    jeffrey.sachs@clalit.org.il   
Sponsors and Collaborators
Meir Medical Center

Responsible Party: Meir Medical Center
ClinicalTrials.gov Identifier: NCT01425606     History of Changes
Other Study ID Numbers: 039-2011
First Posted: August 30, 2011    Key Record Dates
Last Update Posted: August 30, 2011
Last Verified: August 2011

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Hyponatremia
Neoplasms by Histologic Type
Neoplasms
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Water-Electrolyte Imbalance
Metabolic Diseases